Improved GaLV-TR Glycoproteins to Pseudotype Lentiviral Vectors: Impact of Viral Protease Activity in the Production of LV Pseudotypes

Lentiviral vectors (LVs) are excellent tools for gene transfer into mammalian cells. It is noteworthy that the first gene therapy treatment using LVs was approved for commercialization in 2017. The G glycoprotein from rhabdovirus vesicular stomatitis virus (VSV-G) is the glycoprotein most used to ps...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomás, Hélio A., Mestre, Daniel A., Rodrigues, Ana F., Guerreiro, Miguel R., Carrondo, Manuel J.T., Coroadinha, Ana Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742969/
https://www.ncbi.nlm.nih.gov/pubmed/31528654
http://dx.doi.org/10.1016/j.omtm.2019.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742969/
https://www.ncbi.nlm.nih.gov/pubmed/31528654
http://dx.doi.org/10.1016/j.omtm.2019.08.001

Ejemplares similares